Astrazeneca Plc · LSE:AZN
Astrazeneca — ESMO Investor Event 2025
53 slides from Astrazeneca's conference presentation, Oct 20, 2025
Slide 1: Meet AZN Management: ESMO Investor Event
Meet AZN Management: ESMO Investor Event 20 October 2025
Slide 2: Forward-looking statements
Forward-looking statements This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures.
Slide 3: AstraZeneca @ ESMO 2025
AstraZeneca @ ESMO 2025 Furthering the AstraZeneca ambition Pascal Soriot, Chief Executive Officer Key Oncology themes at WCLC and Susan Galbraith, EVP, Oncology Haematology R&D ESMO Redefining the breast cancer landscape • DESTINY-Breast11, DESTINY-Breast05 Prof. Nadia Harbeck, LMU University Hospi
Slide 4: Furthering the AstraZeneca ambition
Furthering the AstraZeneca ambition Pascal Soriot CHIEF EXECUTIVE OFFICER
Slide 5: Ambition – $80bn Total Revenue by 2030 & sustained 2030+ growth
Ambition – $80bn Total Revenue by 2030 & sustained 2030+ growth Beyond 2030 Working on “today, tomorrow and the day after" ADCs and Radioconjugates Illustrative only, not to scale Cell therapy and T-cell engagers Launching key NMEs $80bn Gene therapy AZD0120 saruparib camizestrant volrustomig Next-g
Slide 6: Unprecedented catalyst rich period with key Phase III readouts in 2025 and 2026
Unprecedented catalyst rich period with key Phase III readouts in 2025 and 2026 H2 2025 • H1 2026 • H1 2025 • H2 2026 • DESTINY-Breast09 | Enhertu TROPION-Breast02 | Datroway AVANZAR | Datroway + Imfinzi TROPION-Lung15 | Datroway ± 1L HER2+ breast cancer 1L TNBC 1L NSQ/NSQ TROP2+ NSCLC Tagrisso 2L E
Slide 7: Key Oncology themes at WCLC and ESMO
Key Oncology themes at WCLC and ESMO Susan Galbraith EVP, ONCOLOGY HAEMATOLOGY R&D
Slide 8: >160 abstract acceptances at WCLC and ESMO 2025
>160 abstract acceptances 35 oral presentations 98 poster presentations 4 plenary presentations1 at WCLC and ESMO 2025 Establishing the pipeline for Transforming care today tomorrow – rilvegostomig ex vivo data2 (OA03.03) – DESTINY-Breast11 (291O) – POTOMAC (LBA108) – ARTEMIDE-01 (1853MO) – DESTINY-
Slide 9: Focused strategy to redefine cancer care
Focused strategy to redefine cancer care Significant progress at ESMO and WCLC 2025 DESTINY-Breast11 DESTINY-Breast05 TROPION-Breast02 Novel ADCs and Replace the backbone of chemotherapy Radioconjugates 1 and radiotherapy TROPION- QCS real world FONTANA PanTumor03 implementation Next wave of IO agen
Slide 10: Leading development programme in breast cancer
Leading development programme in breast cancer Early Metastatic Neoadjuvant Adjuvant 1st line 2nd line 3rd line 4th line + Est. epi (G7, 2025) 540k 135k 100k 75k 60k HER2-positive Enhertu → THP NST→ residual disease → Enhertu Enhertu ± pertuzumab Enhertu Enhertu 15-20% DESTINY-Breast11 DESTINY-Breas
Slide 11: DESTINY-Breast11
DESTINY-Breast11 Prof. Nadia Harbeck BREAST CENTER DIRECTOR, LMU UNIVERSITY HOSPITAL, MUNICH
Slide 12: DESTINY-Breast11: Advancing Enhertu into curative early breast cancer setting
DESTINY-Breast11: Advancing Enhertu into curative early breast cancer setting N = 321 Enhertu → THP Primary endpoint: Recommended post-neoadjuvant 4 + 4 cycles treatment per study protocol 1 ― Previously untreated pCR (ypT0/is ypN0) (BICR) HER2+ eBC Secondary endpoints: ― HR+ or HR- Surgery R N = 32
Slide 13: DESTINY-Breast11: Highest reported pCR rate in registrational neoadjuvant HER2+ eBC trial
DESTINY-Breast11: Highest reported pCR rate in registrational neoadjuvant HER2+ eBC trial ITT population (primary endpoint)2 HR–positive HR–negative Δ16% (95% CI 3.0, 28.8) Δ11% (95% CI 4.0, 18.3; P=0.003) Δ9% 83% (95% CI 0.2, 17.9) (n=69/83) 67% 67% (n=216/321) 56% 61% (n=57/85) 52% pCR1 (n=180/320
Slide 14: DESTINY-Breast11: Consistent benefit for Enhertu-THP observed across subgroups
DESTINY-Breast11: Consistent benefit for Enhertu-THP observed across subgroups pCR rate, % (n/N) Enhertu-THP ddAC-THP ΔpCR, % (95% CI) (n=321) (n=320) All patients 67.3 (216/321) 56.3 (180/320) 11.2 (4.0, 18.3) <65 years 66.7 (188/282) 58.0 (167/288) 8.7 (0.7, 16.5) Age at baseline ≥65 years 71.8 (2
Slide 15: DESTINY-Breast11: Promising early EFS trend for Enhertu-THP
DESTINY-Breast11: Promising early EFS trend for Enhertu-THP 96.9% 1.0 (95% CI 93.5, 98.6) Probability of EFS 0.9 93.1% Enhertu-THP ddAC-THP (95% CI 88.7, 95.8) (N=321) (N=320) EFS event rate 11 18 EFS HR (95% CI)1 0.56 (0.26, 1.17) 0.8 0 0 3 6 9 12 15 18 21 24 27 30 33 36 39 No. at risk Time from ra
Slide 16: DESTINY-Breast11: Enhertu-THP demonstrates a favourable safety profile
DESTINY-Breast11: Enhertu-THP demonstrates a favourable safety profile vs ddAC-THP Enhertu-THP ddAC-THP Events, n (%) (n=320)1 (n=312) 1 Any AE 314 (98.1) 308 (98.7) Grade ≥3 120 (37.5) 174 (55.8) Any serious AE 34 (10.6) 63 (20.2) AE leading to any dose reduction 58 (18.1) 60 (19.2) AE leading to a
Slide 17: DESTINY-Breast11: Enhertu-THP potential to be preferred regimen
DESTINY-Breast11: Enhertu-THP potential to be preferred regimen for patients with high-risk HER2+ eBC ― Enhertu-THP showed a 67% pCR rate, the highest reported in a HER2+ eBC registrational study in the neoadjuvant setting, despite a high-risk, predominantly HR+ population ― Early positive trend in
Slide 18: DESTINY-Breast05
DESTINY-Breast05 Prof. Nadia Harbeck BREAST CENTER DIRECTOR, LMU UNIVERSITY HOSPITAL, MUNICH
Slide 19: DESTINY-Breast05: Moving Enhertu into high-risk post-neoadjuvant setting
DESTINY-Breast05: Moving Enhertu into high-risk post-neoadjuvant setting N = 818 Primary endpoint: Enhertu IDFS (inv) 14 cycles ― High-risk1 HER2+ eBC Key secondary endpoint: ― Residual disease after DFS (inv) neoadjuvant chemotherapy R 1:1 and preoperative Secondary endpoints: HER2-directed treatme
Slide 20: DESTINY-Breast05: Enhertu reduced risk of invasive disease recurrence or death by 53%
DESTINY-Breast05: Enhertu reduced the risk of invasive disease recurrence or death by 53% vs T-DM1 92.4% Invasive Disease-Free Survival1 1.0 0.8 83.7% Enhertu T-DM1 (N=818) (N=817) 0.6 IDFS event rate 51 (6.2) 102 (12.5) IDFS HR (95% CI) 0.47 (0.34-0.66), P < 0.00012 0.0 0 2 4 6 8 10 12 14 16 18 20
Slide 21: DESTINY-Breast05: Secondary endpoints supportive of Enhertu benefit
DESTINY-Breast05: Secondary endpoints supportive of Enhertu benefit vs T-DM1 92.3% 1.0 Disease-Free Survival1 0.8 83.5% Enhertu (N=818) T-DM1 (N=817) 0.6 DFS event rate 52 (6.4) 103 (12.6) DFS HR (95% CI) 0.47 (0.34-0.66), P < 0.00012 0.0 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42
Slide 22: DESTINY-Breast05: Generally manageable AE profile
DESTINY-Breast05: Generally manageable AE profile consistent with prior trials of Enhertu Enhertu T-DM1 n=8061 n=8011 TEAEs, n (%) Any-grade 802 (99.5) 788 (98.4) Grade ≥3 408 (50.6) 416 (51.9) Serious 140 (17.4) 109 (13.6) Associated with drug 144 (17.9) 103 (12.9) discontinuation Related to drug-r
Slide 23: DESTINY-Breast05: Potential new standard-of-care in high-risk HER2+ eBC
DESTINY-Breast05: Post-neoadjuvant Enhertu potential new standard-of-care in high-risk HER2+ eBC ― Enhertu showed a statistically significant and clinically meaningful IDFS and DFS benefit versus T-DM1 in patients with HER2+ eBC with residual invasive disease and high risk of recurrence after neoadj
Slide 24: TROPION-Breast02
TROPION-Breast02 Prof. Rebecca Dent HEAD OF DEPARTMENT OF MEDICAL ONCOLOGY, CHIEF OF BREAST MEDICAL ONCOLOGY, NATIONAL CANCER CENTER SINGAPORE
Slide 25: TROPION-Breast02: Establishing Datroway in 1L TNBC with positive overall survival data
TROPION-Breast02: Establishing Datroway in 1L TNBC with positive overall survival data ― Locally recurrent inoperable or metastatic TNBC Dual primary endpoints: N = 323 ― No prior chemotherapy or Datroway PFS (BICR), OS targeted systemic therapy in the locally recurrent inoperable or metastatic R 1:
Slide 26: TROPION-Breast02: Datroway reduced risk of progression or death by 43%
TROPION-Breast02: Datroway reduced the risk of progression or death by 43% vs chemotherapy Datroway ICC 1.0 PFS events, n (%) 199 (62) 209 (65) 0.9 12-mo rate: mPFS, mo 10.8 5.6 0.8 45.6% 18-mo rate: HR (95% CI) 0.57 (0.47–0.69) Probability of PFS 0.7 25.6% P-value <0.0001 32.7% 0.6 16.8% 0.5 0.4 0.
Slide 27: TROPION-Breast02: Datroway improved overall survival
TROPION-Breast02: Datroway improved overall survival by 5 months vs chemotherapy Datroway ICC 1.0 OS events, n (%) 168 (52) 181 (56) 12-mo rate: 0.9 75.2% mOS, mo 23.7 18.7 0.8 67.8% 18-mo rate: HR (95% CI) 0.79 (0.64–0.98) 61.2% Probability of OS 0.7 P-value 0.0291 51.3% 0.6 0.5 0.4 0.3 0.2 0.1 0 0
Slide 28: TROPION-Breast02: Datroway improved objective response rate by 33%
TROPION-Breast02: Datroway improved objective response rate by 33% vs chemotherapy Datroway ICC Δ 33.2% (n=323) (n=321) Confirmed ORR, n (%) 202 (62.5) 94 (29.3) ORR 62.5% Odds ratio (95% CI) 4.24 (3.03–5.95) CR Best confirmed objective response, n (%) ORR 29.3% Complete response 29 (9.0) 8 (2.5) CR
Slide 29: TROPION-Breast02: Manageable and tolerable safety profile
TROPION-Breast02: Manageable and tolerable safety profile throughout longer duration of therapy Treatment-related Datroway (n=319) ICC (n=309) AEs1, n (%) Any Grade Grade ≥3 Any Grade Grade ≥3 Datroway ICC (n=319) (n=309) Dry eye2 76 (24) 4 (1) 9 (3) 0 Stomatitis 182 (57) 27 (8) 27 (9) 0 Median tota
Slide 30: TROPION-Breast02: Datroway potential new 1L SoC for TNBC
TROPION-Breast02: Datroway to be potential new 1L SoC for patients with TNBC for whom IO is not an option ― TROPION-Breast02 met both dual primary endpoints: first-line Datroway demonstrated statistically significant and clinically meaningful improvement in OS and PFS over CTx ― 5 mo improvement in
Slide 31: Realising our ambition in breast cancer
Realising our ambition in breast cancer Sunil Verma SVP, GLOBAL HEAD, ONCOLOGY FRANCHISE
Slide 32: Moving Enhertu into early HER2+ disease increasing probability of cure
Moving Enhertu into early HER2+ disease increasing probability of cure Potential new early breast cancer treatment paradigm DESTINY-Breast11 DESTINY-Breast05 34k patients in G7 | neoadj. HER2+ eBC1 34k patients in G7 | neoadj. HER2+ eBC1 80% | high-risk disease (prior to 50% | residual disease after
Slide 33: Enhertu opportunity to span continuum of HER2+ breast cancer
Enhertu opportunity to span continuum of HER2+ breast cancer Early Metastatic Neoadjuvant Post-neoadjuvant 1st line 2nd line 3rd line + Est. epi (G7, 2024) 34k 23k 17k 11k To be shared with Regulatory decision H1’26 Regulatory decision H1’26 Approved Approved regulatory authorities RECURRENCE neoadj
Slide 34: Datroway redefining treatment in high unmet need TNBC population
Datroway redefining treatment in high unmet need TNBC population TROPION-Breast02 | First and only therapy Broadening Datroway impact in TNBC to significantly improve overall survival vs CTx with Imfinzi combinations in TNBC where IO is not an option1 BEGONIA Phase Ib/II data drive confidence in com
Slide 35: Opportunity for Q&A on breast cancer
Opportunity for Q&A on breast cancer Key External Experts Dr Rebecca Dent Prof. Nadia Harbeck HEA D O F DEP AR T MENT O F ME DIC A L BR EA S T C EN TER DI R EC TO R , L MU O NC O LOG Y, C HI EF O F BR EA S T UN I VER S I TY HOS P IT AL, MUN IC H ME DIC A L O NC O LO GY, N ATI O NA L C AN C ER C EN T
Slide 36: POTOMAC
POTOMAC Dr Neal Shore MEDICAL DIRECTOR, START- CAROLINA UROLOGIC RESEARCH CENTER
Slide 37: POTOMAC: Transforming patient outcomes in a curative intent setting
POTOMAC: Transforming patient outcomes in a curative intent setting ― NMIBC I+BCG (I+M) Imfinzi (13 cycles) N=339 Primary endpoint: ― BCG-naïve BCG induction 2 BCG maintenance3 DFS: I+BCG (I+M) vs BCG ― High-risk tumour defined as any of the following: (I+M) I+BCG (I only) Imfinzi (13 cycles) Key se
Slide 38: POTOMAC: Imfinzi + BCG reduced risk of a DFS event by 32%
POTOMAC: Imfinzi + BCG (I+M) reduced the risk of a DFS event by 32%, with an early and sustained benefit 1.0 92% 87% 82% 0.8 87% 82% 77% Probability of DFS 0.6 I+BCG (I+M) BCG (I+M) 0.4 N=339 N=340 DFS events, n (%) 67 (20) 98 (29) 0.2 mDFS, mo NR NR HR (95% CI) 0.68 (0.50–0.93) P-value 0.0154 0 0 3
Slide 39: POTOMAC: Generally consistent DFS benefit across subgroups
POTOMAC: Generally consistent DFS benefit across subgroups for Imfinzi + BCG (I+M) 1. With or without papillary disease as recorded per interactive voice response system. 2. Defined as T1G3/T1 high-grade or multiple and recurrent and large tumours (those with a diameter of ≥3 cm). 3. Assessed with t
Slide 40: POTOMAC: No evidence of OS detriment with Imfinzi + BCG
POTOMAC: No evidence of OS detriment with Imfinzi + BCG (I+M) 1.0 0.8 Probability of OS 0.6 I+BCG (I+M) BCG (I+M) 0.4 N=339 N=340 Deaths, n (%) 41 (12) 52 (15) 0.2 mOS, mo NR NR HR (95% CI) 0.80 (0.53–1.20) 0 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54 57 60 63 66 69 72 75 79 81 84 Time fro
Slide 41: POTOMAC: AE profile was tolerable and manageable
POTOMAC: AE profile was tolerable and manageable, and consistent with known profiles of individual therapies I+BCG (I+M) BCG (I+M) Events, n (%) n=336 n=339 TRAEs of any cause 325 (97) 307 (91) Maximum Grade 3 or 4 TRAE 71 (21) 13 (4) Serious TRAEs 45 (13) 13 (4) TRAEs leading to death 0 0 AEs leadi
Slide 42: POTOMAC: Imfinzi + BCG potential to change course of high-risk NMIBC
POTOMAC: Imfinzi + BCG potential to change the course of high-risk non-muscle-invasive bladder cancer ― Imfinzi in combination with BCG induction and maintenance resulted in a statistically significant and clinically meaningful improvement in DFS vs BCG induction and maintenance alone in patients wi
Slide 43: Realising our ambition in GU cancers and beyond
Realising our ambition in GU cancers and beyond Dave Fredrickson EVP, ONCOLOGY HAEMATOLOGY BUSINESS
Slide 44: Building Imfinzi as a backbone in bladder cancer
Building Imfinzi as a backbone in bladder cancer POTOMAC | Moving Imfinzi Imfinzi CDP covers key stages of bladder cancer into earlier stages of bladder High-risk NMIBC MIBC 1L mUC cancer 96k2 68k2 46k2 Drug-treated patients 96k with high-risk NMIBC NIAGARA across G7 Neoadj. Imfinzi + CTx → adj. Imf
Slide 45: AstraZeneca commercial strategy to transform patient outcomes
AstraZeneca commercial strategy to transform patient outcomes Medicines that matter Leveraging scale Transforming patient care Building transformative brands Tumour area leadership Closing the care gap Breast Gastrointestinal Precision Early detection diagnostics GYN/GU Haematology Guideline-based P
Slide 46: Opportunity for Q&A
Opportunity for Q&A Key External Expert Prof. Neal Shore ME DIC A L DI R EC TO R , S TA R T- C AR O LI NA U R OL OGI C R ES EAR C H C ENT ER AstraZeneca Leadership Pascal Soriot Dave Fredrickson EV P, O NC O LO GY C HI EF EX EC UT IV E O F F I CE R HA EMA TOL OGY BUS I NE SS Susan Galbraith Leora Ho
Slide 47: Glossary
Glossary • (a)BTC (advanced) biliary tract cancer GC gastric cancer ORR objective response rate 1L, 2L, 3L first-, second-, third-line GEJ(A) gastroesophageal junction (adenocarcinoma) OS overall survival a/mBC advanced/metastatic breast cancer gMG generalised myasthenia gravis P pertuzumab ADC anti
Slide 48: Confidentiality Notice
Confidentiality Notice This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or dis
Slide 49: Meet AZN Management: WCLC and ESMO – Appendix
Meet AZN Management: WCLC and ESMO APPENDIX
Slide 50: AstraZeneca in non-small cell lung cancer
A PP END I X | Oncology tumour maps AstraZeneca in non-small cell lung cancer Resectable Unresectable Metastatic Stg. I Stg. II-III Stg. I-II Stg. III 1L 2L 3L+ Est. epi (G7, 2025) ~150K ~70K ~50K ~100K ~310K ~190K ~70K Imfinzi CRT → Imfinzi Imfinzi + Imjudo + CTx POSEIDON AEGEAN PACIFIC Datroway +
Slide 51: AstraZeneca in breast cancer
A PP END I X | Oncology tumour maps AstraZeneca in breast cancer Early Metastatic Neoadjuvant Adjuvant 1st line 2nd line 3rd line 4th line + Est. epi (G7, 2025) 540k 135k 100k 75k 60k HER2-positive Enhertu → THP NST→ residual disease → Enhertu Enhertu ± pertuzumab Enhertu Enhertu 15-20% DESTINY-Brea
Slide 52: AstraZeneca in gastric cancer
A PP END I X | Oncology tumour maps AstraZeneca in gastric cancer Early Advanced/Metastatic Stage II/III 1st line 2nd line 3rd line Est. epi (G7, 2025) 50k 90k 60k 30k Enhertu + rilvegostomig + FP HER2-positive ARTEMIDE-Gastric01 Enhertu Enhertu 20% DESTINY-Gastric02, 04 DESTINY-Gastric01 Enhertu +
Slide 53: Significant progress with transformative technologies to drive 2030+ growth
Significant progress with transformative technologies to drive 2030+ growth Weight management ADCs and Cell therapy and Gene therapy and Next-gen IO bispecifics and risk factors Radioconjugates T-cell engagers gene editing Establish and lead Develop scalable cell Replace systemic Make cure possible